Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); Raising PT and Estimates
Tweet Send to a FriendGet Alerts GILD Hot Sheet
Price: $56.60 +1.54%
Rating Summary:
17 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 24
Rating Summary:
17 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 24
Trade GILD Now!
Needham & Company reiterates a 'Buy' on Gilead Sciences (NASDAQ: GILD) price target of $65.00 (from $56.00).
Analyst, Alan Carr, said, "Gilead announced yesterday that the FDA has approved Stribild (Quad Pill) for the treatment of HIV infection. Stribild is a fixed dose combination of emtricitabine, tenofovir, elvitegravir, and cobicistat. The company expects the drug to be commercially available by mid-week. WAC pricing is $2342/month, a premium compared to Atripla ($1734) and Complera ($1830). Although Gilead’s efforts in HCV are drawing more attention, we believe the HIV franchise still represents a meaningful growth opportunity for the company due to several favorable factors, including: Guidelines calling for immediate initiation of
treatment are likely to expand the market; Gilead will now have three single-tablet regimen options on the market, with more in development containing GS7340 as a replacement for tenofovir; and last, we expect margins to gradually improve as patients transition to Complera and Stribild." (FY13 EPS estimate raised by $0.02 to $4.35)
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.19 yesterday, with a 52 week range of $34.45-$58.84.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Alan Carr, said, "Gilead announced yesterday that the FDA has approved Stribild (Quad Pill) for the treatment of HIV infection. Stribild is a fixed dose combination of emtricitabine, tenofovir, elvitegravir, and cobicistat. The company expects the drug to be commercially available by mid-week. WAC pricing is $2342/month, a premium compared to Atripla ($1734) and Complera ($1830). Although Gilead’s efforts in HCV are drawing more attention, we believe the HIV franchise still represents a meaningful growth opportunity for the company due to several favorable factors, including: Guidelines calling for immediate initiation of
treatment are likely to expand the market; Gilead will now have three single-tablet regimen options on the market, with more in development containing GS7340 as a replacement for tenofovir; and last, we expect margins to gradually improve as patients transition to Complera and Stribild." (FY13 EPS estimate raised by $0.02 to $4.35)
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.19 yesterday, with a 52 week range of $34.45-$58.84.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Urban Outfitters (URBN) Added to Best Ideas List at Janney Capital on Solid Q1 Results
- UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
